The invention relates to the use of a central cannabinoid receptor antagonist for the preparation of medicinal products that are useful in treating and preventing neuroinflammatory pathologies.

N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-car boxamide and its salts and solvates are powerful antagonists of the CB.sub.1 cannabinoid receptors. They are prepared by reacting a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, optionally followed by salification.

The invention relates to compounds having formula (I): ##STR00001## Wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined herein. The invention also relates to a method of preparing said compounds and to die application thereof in therapeutics.

N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole -3-carboxamide and its salts and solvates are powerful antagonists of the CB.sub.1 cannabinoid receptors. They are prepared by reacting a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, optionally followed by salification.

The present invention relates, among many things, to novel 4,5-dihydro-1H-pyrazole compounds which can be potent antagonists of the cannabis CB.sub.1 -receptor. The compounds have the formula (I) ##STR1## wherein R and R.sub.1 are the same or different and represent unsubstituted or substituted phenyl, thienyl, or pyridyl, or naphthyl. naphthyl R.sub.2 represents hydrogen, hydroxy, C.sub.1-3 -alkoxy, acetyloxy or propionyloxy, Aa represents one of the groups (i), (ii), (iii), (iv) or (v) as defined herein, Bb represents sulfonyl or carbonyl, and R.sub.3 represents benzyl, phenyl, thienyl or pyridyl, each of which is unsubstituted or substituted, or R.sub.3 represents C.sub.1-8 branched or unbranched alkyl or C.sub.3-8 cycloalkyl, or R.sub.3 represents naphthyl.